Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(19)30279-8 ◽

2019 ◽

Vol 19 (10) ◽

pp. 1091-1100 ◽

Cited By ~ 22

Author(s):

Sonya Abraham ◽

Helene B Juel ◽

Peter Bang ◽

Hannah M Cheeseman ◽

Rebecca B Dohn ◽

...

Keyword(s):

Aluminium Hydroxide ◽

Vaccine Candidate ◽

Phase 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

The Lancet ◽

10.1016/s0140-6736(17)33106-9 ◽

2018 ◽

Vol 391 (10120) ◽

pp. 563-571 ◽

Cited By ~ 100

Author(s):

Kayvon Modjarrad ◽

Leyi Lin ◽

Sarah L George ◽

Kathryn E Stephenson ◽

Kenneth H Eckels ◽

...

Keyword(s):

Clinical Trials ◽

Virus Vaccine ◽

Zika Virus ◽

Vaccine Candidate ◽

Phase 1 ◽

Controlled Clinical Trials ◽

Double Blind ◽

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00241-5 ◽

2021 ◽

Vol 397 (10275) ◽

pp. 682-694 ◽

Cited By ~ 2

Author(s):

Peter Richmond ◽

Lara Hatchuel ◽

Min Dong ◽

Brenda Ma ◽

Branda Hu ◽

...

Keyword(s):

Subunit Vaccine ◽

Vaccine Candidate ◽

Controlled Trial ◽

Phase 1 ◽

Healthy Adults ◽

Protein Subunit ◽

Double Blind ◽

Decision letter for "A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults"

10.1002/jbmr.4016/v3/decision1 ◽

2020 ◽

Keyword(s):

Phase 1 ◽

Healthy Adults ◽

Double Blind ◽

Double Blind Placebo ◽

Review for "A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults"

10.1002/jbmr.4016/v1/review2 ◽

2019 ◽

Keyword(s):

Phase 1 ◽

Healthy Adults ◽

Double Blind ◽

Double Blind Placebo ◽

YH12852, a Novel and Highly Selective 5-hydroxytryptamine 4 Receptor Agonist, Increases Stool Frequency in Healthy Volunteers and Patients with Functional Constipation: Results of a Randomized Double-blind Placebo/active-controlled Phase 1/2a Trial

10.26226/morressier.59a6b348d462b80290b5501d ◽

2017 ◽

Author(s):

Seoungoh Lee

Keyword(s):

Healthy Volunteers ◽

Receptor Agonist ◽

Phase 1 ◽

Functional Constipation ◽

Stool Frequency ◽

Double Blind ◽

Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717967956.793467610 ◽

2012 ◽

Author(s):

Robin Steinhorn

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Sildenafil Citrate ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

Dose Ranging ◽

Pulmonary Arterial

Faculty Opinions recommendation of A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics-Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single Ascending Bolus Dose.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727567304.793536193 ◽

2017 ◽

Author(s):

Harald Ihmsen

Keyword(s):

Healthy Subjects ◽

Bolus Dose ◽

Phase 1 ◽

Controlled Study ◽

Clinical Effects ◽

Single Center ◽

Double Blind ◽

A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19

The Lancet Regional Health - Europe ◽

10.1016/j.lanepe.2021.100084 ◽

2021 ◽

pp. 100084

Author(s):

Vibeke Backer ◽

Ulf Sjöbring ◽

Jesper Sonne ◽

Anne Weiss ◽

Morten Hostrup ◽

...

Keyword(s):

Broad Spectrum ◽

Phase 1 ◽

Double Blind ◽

Double Blind Placebo ◽

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail

British Journal of Dermatology ◽

10.1111/bjd.19224 ◽

2020 ◽

Cited By ~ 1

Author(s):

B. Elewski ◽

S. Brand ◽

T. Degenhardt ◽

S. Curelop ◽

R. Pollak ◽

...

Keyword(s):

Phase Ii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging